Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.61 USD | +1.18% |
|
+2.50% | -17.13% |
17/06 | Zymeworks Says FDA Clears Investigational New Drug Application for Cancer Therapy | MT |
17/06 | Zymeworks Gets FDA OK to Study ZW171 for Mesothelin-Expressing Cancers | DJ |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-17.13% | 61Cr | |
+15.82% | 12TCr | |
+20.35% | 11TCr | |
+18.52% | 2.57TCr | |
-25.31% | 1.9TCr | |
-21.11% | 1.58TCr | |
-19.67% | 1.53TCr | |
-46.87% | 1.49TCr | |
+62.55% | 1.48TCr | |
+6.34% | 1.41TCr |
- Stock Market
- Equities
- ZYME Stock
- News Zymeworks Inc.
- Wells Fargo Raises Price Target for Zymeworks to $12 From $9, Maintains Overweight Rating